TFF3 and neoplasm: Studies showed that AMPC dose-dependently decreased TFF3 expression in estrogen-receptor-positive mammary carcinoma cells, lung adenocarcinoma cells, and mesenchymal colorectal carcinoma cells, which induced tumor-volume reduction in mice [78, 91, 92].